Medical Developments International Ltd
ASX:MVP
Intrinsic Value
Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. [ Read More ]
The intrinsic value of one
MVP
stock under the Base Case scenario is
1.72
AUD.
Compared to the current market price of 0.44 AUD,
Medical Developments International Ltd
is
Undervalued by 74%.
Medical Developments International Ltd's market capitalization is 38m AUD.
MVP stock price is 0.44 AUD.
MVP stock price (0.44 AUD) is 74% less than its Intrinsic Value (1.72 AUD).
MVP has upside potential of 264% compared to the average analyst price target.
Open Wall St Estimates
MVP's Revenue has grown by an exceptional 27% over the past 12 months.
MVP's Revenue has been growing by 11% per year for the last 3 years.
MVP's Revenue is forecast to grow at a rate of 29% per year over the next 3 years.
MVP's ROE (Return on Equity) has significantly decreased in the last 3 years from -2% to -23%, and is approaching profitability.
MVP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -2% to -33%, and is approaching profitability.
MVP has negative Operating Income for the last twelve months.
MVP has negative Net Income for the last twelve months.
MVP's ROE (Return on Equity) for the past 12 months is negative and is equal to -23%.
MVP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -33%.
MVP's Altman Z-Score is very low and is equal to 1.61.
MVP has positive Gross Profit for the last twelve months.
MVP's short-term assets (31m AUD) exceed its short-term liabilties (11m AUD).
MVP has negative Free Cash Flow for the last twelve months.
MVP has negative three-year average ROE (Return on Equity): -15%. The company is not efficient at transforming stockholders' equity into net income.
MVP has negative three-year average ROIC (Return on Invested Capital): -18%. The company is not efficient at using invested capital to generate operating income.
MVP's D/E (Debt to Equity) is very low and is equal to 0.03.
MVP's long-term assets (91m AUD) exceed its long-term liabilties (15m AUD).
MVP has negative Net Debt. This means that the company has more cash and short-term investments (16m AUD) than debt (2m AUD).
MVP earns more than enough operating income (-25m AUD) to safely cover interest payments on its debt (-95k AUD).
Valuation Backtest
Medical Developments International Ltd
Run backtest to discover the historical profit from buying and selling
MVP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Medical Developments International Ltd
Balance Sheet Decomposition
Medical Developments International Ltd
| Current Assets | 31m |
| Cash & Short-Term Investments | 15.7m |
| Receivables | 4.8m |
| Other Current Assets | 10.5m |
| Non-Current Assets | 60m |
| PP&E | 11.7m |
| Intangibles | 38.5m |
| Other Non-Current Assets | 9.8m |
| Current Liabilities | 11.2m |
| Accounts Payable | 9.8m |
| Accrued Liabilities | 697k |
| Other Current Liabilities | 648k |
| Non-Current Liabilities | 4.2m |
| Long-Term Debt | 2.1m |
| Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Medical Developments International Ltd
|
Revenue
|
33.5m
AUD
|
|
Cost of Revenue
|
-10.2m
AUD
|
|
Gross Profit
|
23.3m
AUD
|
|
Operating Expenses
|
-48.4m
AUD
|
|
Operating Income
|
-25.1m
AUD
|
|
Other Expenses
|
5.9m
AUD
|
|
Net Income
|
-19.2m
AUD
|
Free Cash Flow Analysis
Medical Developments International Ltd
MVP Profitability Score
Profitability Due Diligence
Medical Developments International Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Medical Developments International Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
MVP Solvency Score
Solvency Due Diligence
Medical Developments International Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Medical Developments International Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MVP Price Targets Summary
Medical Developments International Ltd
According to Wall Street analysts, the average 1-year price target for
MVP
is 1.6 AUD
.
Shareholder Return
MVP Price
Medical Developments International Ltd
| Average Annual Return | -13.51% |
| Standard Deviation of Annual Returns | 57.47% |
| Max Drawdown | -96% |
| Market Capitalization | 38m AUD |
| Shares Outstanding | 86 305 211 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Medical Developments International Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The company is headquartered in Melbourne, Victoria and currently employs 68 full-time employees. The company went IPO on 2003-12-15. The firm is focused on manufacturing and distributing pharmaceutical drugs, and medical and veterinary equipment. The firm operates through three segments: Pharmaceuticals, Medical Devices and Veterinary Products. The Pharmaceuticals segment is engaged in the sale of Penthrox primarily within Australia, New Zealand, Europe and the United Kingdom, and some sales in the Middle East, Asia and South Africa. The Medical Devices segment is engaged in the sale of medical devices, particularly the Space Chamber and Breath-Alert PeakFlow meters, primarily within Australia, the United Kingdom/Europe, North America, and some sales in Asia and New Zealand. The Veterinary Products segment is engaged in the sale of veterinary products within Australia, Europe, and Asia.
Contact
IPO
Employees
Officers
The intrinsic value of one
MVP
stock under the Base Case scenario is
1.72
AUD.
Compared to the current market price of 0.44 AUD,
Medical Developments International Ltd
is
Undervalued by 74%.
You don't have any saved screeners yet
